Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VRCA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $47.07M
- EPS (TTM)
- -$2.30
- Dividend yield
- None
- 52-week range
- 2.73 – 9.82
- Day range
- 2.73 – 2.96
- Volume / Avg
- 127.03K / 68.78K
- Beta
- —
- Shares outstanding
- 17.18M
52-week range
VRCA stock today
On Nov 20, VRCA ended the session at $2.74, shedding $0.145 (5.03%), versus the S&P 500's 3.70% decline. At this level, VRCA sits near the bottom of its 52-week range of $2.73 to $9.82: 72.1% below the high, set on Nov 28, 2025 and 0.4% above the low. VRCA is down 67.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.9%.
Verrica Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Verrica Pharmaceuticals
Company profileVerrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jayson M. Rieger M.B.A., Ph.D.
- Headquarters
- West Chester, PA
- Employees
- 76
- IPO year
- 2018
- Website
- verrica.com
Financial highlights
Full financialsIn fiscal 2025, Verrica Pharmaceuticals generated $35.6 million in revenue, up 370.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Verrica Pharmaceuticals reported a net loss of $17.9 million, compared with a loss of $76.6 million a year earlier. Operating margin was -34.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $35.58M | $7.57M | $5.12M | $9.03M | $12.00M |
| Growth | +370.22% | +47.66% | -43.27% | -24.73% | — |
| Net income | $-17.89M | $-76.58M | $-67.00M | $-24.49M | $-35.08M |
| EPS (diluted) | $-1.68 | $-14.78 | $-1.48 | $-0.72 | $-1.30 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$13.83+404.74%
- Strong buy 0
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.05 vs $-0.50
- Surprise
- +110.00%
VRCA news
All VRCA news- Verrica (VRCA) Q3 2026 Earnings Call TranscriptNasdaqVRCA, BIO.B
- Verrica Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityGlobeNewswire
Verrica Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NMADNomad Power Solutions Inc. | 2.56 | +13.53% | $47.15M | vs VRCA |
| ONCYOncolytics Biotech Inc. | 0.3501 | -10.37% | $47.66M | vs VRCA |
| TNXPTonix Pharmaceuticals Holding Corp. | 2.38 | -6.67% | $46.25M | vs VRCA |
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs VRCA |
| RFLRafael Holdings Inc. Class B | 0.9197 | +2.19% | $47.99M | vs VRCA |
| HRTXHeron Therapeutics Inc. | 0.2525 | -4.39% | $48.04M | vs VRCA |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs VRCA |
| RNXTRenovoRx Inc. | 0.942 | -10.29% | $45.45M | vs VRCA |
Indexes, lists and sector
Verrica Pharmaceuticals stock FAQ
What is Verrica Pharmaceuticals's stock price today?
VRCA last traded at $2.74 as of Nov 20, 4:00 PM EST, down 5.03% on the day. Prices are delayed at least 15 minutes.
Does Verrica Pharmaceuticals pay a dividend?
No. Verrica Pharmaceuticals does not currently pay a regular cash dividend.
Who is Verrica Pharmaceuticals's CEO?
Dr. Jayson M. Rieger M.B.A., Ph.D. is the chief executive officer of Verrica Pharmaceuticals Inc., which has about 76 employees.
Has VRCA ever split its stock?
Yes. The most recent VRCA stock split was a 1-for-10 split on Jul 25, 2025.
What is the VRCA 52-week high?
The 52-week high for VRCA is $9.82 and the 52-week low is $2.73. The stock is currently 72.1% below its high.